STAMPEDE (part 3): Impact and legacy with Max Parmar & Nick James

MRC CTU Podcasts

Contenido proporcionado por MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

1+ y ago 23:23

MP3•Episodio en casa

STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. In the final part, Max Parmar and Nick James look back over the trial’s impact on clinical practice and platform trial design and look forward to STAMPEDE2, sharing their hopes for the future of prostate cancer research. - Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: bit.ly/3OQWhV8 As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

25 episodios

#Science #Medicine #MRC Clinical Trials Unit At UCL